Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

PHASE3RecruitingINTERVENTIONAL
Enrollment

830

Participants

Timeline

Start Date

May 28, 2025

Primary Completion Date

March 14, 2031

Study Completion Date

April 15, 2031

Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
DRUG

Abiraterone

Assigned prior to enrollment

DRUG

Enzalutamide

Assigned prior to enrollment

DRUG

Apalutamide

Assigned prior to enrollment

DRUG

Darolutamide (BAY 1841788)

Assigned prior to enrollment

DRUG

Docetaxel

Assigned at enrollment

DRUG

ADT

Physician's choice. Assigned prior to enrollment

Trial Locations (1)

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ECOG-ACRIN Cancer Research Group

NETWORK

collaborator

NRG Oncology

OTHER

collaborator

Alliance for Clinical Trials in Oncology

OTHER

collaborator

SWOG Cancer Research Network

NETWORK

lead

Canadian Cancer Trials Group

NETWORK